Bio-Matrix Scientific Group, Inc. (OTCMKTS:BMSN) Files An 8-K Other Events
Item 8.01 Other Events
On January 10, 2017 Regen Biopharma, Inc. ( Regen) filed a
CERTIFICATE OF DESIGNATION (Certificate of Designations) with the
Nevada Secretary of State setting forth the preferences rights
and limitations of a newly authorized series of preferred stock
designated and known as Series M Preferred Stock (hereinafter
referred to as Series M Preferred Stock).
The Board of Directors of Regen have authorized 300,000,000
shares of the Series M Preferred Stock, par value $0.0001. With
respect to each matter submitted to a vote of stockholders of
Regen, each holder of Series A Preferred Stock shall be entitled
to cast that number of votes which is equivalent to the number of
shares of Series M Preferred Stock owned by such holder times
one. Except as otherwise required by law holders of Common Stock,
other series of Preferred issued by Regen, and Series M Preferred
Stock shall vote as a single class on all matters submitted to
the stockholders.
With respect to each matter submitted to a vote of stockholders
of Regen, each holder of Series M Preferred Stock shall be
entitled to cast that number of votes which is equivalent to the
number of shares of Series M Preferred Stock owned by such holder
times one (1). Except as otherwise required by law, holders of
Common Stock, other series of Preferred issued by Regen, and
Series M Preferred Stock shall vote as a single class on all
matters submitted to the stockholders.
The holders of Series M Preferred Stock shall be entitled receive
dividends, when, as and if declared by the Board of Directors in
accordance with Nevada Law, in its discretion, from funds legally
available therefore
On any voluntary or involuntary liquidation, dissolution or
winding up of Regen, the holders of the Series M Preferred Stock
shall receive, out of assets legally available for distribution
to Regens stockholders, a ratable share in the assets of Regen.
On December 27, 2016 7,500,000 shares of Regens common stock
personally owned by Todd S. Caven, Regens Chief Financial
Officer, were cancelled by Regen. On December 27, 2016 2,500,000
shares of Regens Series A Preferred personally owned by Todd S.
Caven were cancelled by Regen. No consideration was paid by Regen
to Mr. Caven for these cancellations.
Regen is a controlled subsidiary of Bio-Matrix Scientific Group,
Inc.
Item 9.01 Exhibits
| Exhibit No. | Description of Exhibit | |
| 3(i) | Text of Certificate of Designations |
About Bio-Matrix Scientific Group, Inc. (OTCMKTS:BMSN)
Bio-Matrix Scientific Group, Inc., through its subsidiary, Regen BioPharma, Inc., is engaged in the development of regenerative medical applications. The Company focuses on licensing from other entities up to the point of successful completion of Phase I and or Phase II clinical trials, after which it intends to sell or license those developed applications or advance the application further to Phase III clinical trials. Its products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax and Small Molecules. The Company is focused on the development of HemaXellerate I, a cellular therapy designed to heal damaged bone marrow. HemaXellerate II is intended to be a universal donor endothelial cell-based therapeutic. dCellVax is intended to be a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is intended to be an autologous cellular product. The Company identifies small molecules via a high throughput screening program. Bio-Matrix Scientific Group, Inc. (OTCMKTS:BMSN) Recent Trading Information
Bio-Matrix Scientific Group, Inc. (OTCMKTS:BMSN) closed its last trading session 00.00000 at 0.00010 with 100,000 shares trading hands.
